scholarly journals Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan

2019 ◽  
Vol 49 (8) ◽  
pp. 766-771 ◽  
Author(s):  
Takeo Kosaka ◽  
Hiroji Uemura ◽  
Makoto Sumitomo ◽  
Kenichi Harada ◽  
Mikio Sugimoto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Primary Prophylaxis ◽  
Granulocyte Colony Stimulating Factor ◽  
Castration Resistant Prostate Cancer ◽  
Open Label ◽  
Effective Treatment Option ◽  
Open Label Study ◽  
Castration Resistant ◽  
Stimulating Factor

Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) reduced incidence of febrile neutropenia in Japanese metastatic castration-resistant prostate cancer patients. Cabazitaxel+G-CSF therapy was a safe and effective treatment option.

A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e16071-e16071 ◽  
Author(s):  
David I. Quinn ◽  
Daniel Peter Petrylak ◽  
Christopher Michael Pieczonka ◽  
Andrew Sandler ◽  
Todd DeVries ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Castration Resistant Prostate Cancer ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Castration Resistant ◽  
Randomized Phase Ii
Sign in / Sign up

Export Citation Format

Share Document